1 The Department of Pediatrics and Radiology, University of Toronto and Research Institute, The Hospital for Sick Children, Toronto
The efficacy, adverse reactions, and long-term effects of intestinal lavage treatment with a balanced electrolyte solution (Golytely) was evaluated in patients with cystic fibrosis and distal intestinal obstruction syndrome. Twenty-two patients with cystic fibrosis (mean age 21.8 years, range 14 to 34 years, 15 boys or men) who sought medical attention because of abdominal pain and a mass in the right iliac fossa received Golytely, 5.6 ± 1.9 L (mean ± 1 SD), either orally (n = 14) or via nasogastric tube (n = 8) during 5.6 ± 2.4 hours. No serious side effects occurred. Serum electrolyte values remained within normal limits. Body weight did not change significantly. Minor adverse reactions included bloating (n = 12), nausea (n = 8), vomiting (n = 1), and chills (n = 3). All but one patient reported impressive relief of symptoms and remained pain free for an average of 3 months (range 1 to 19 months). Symptoms of abdominal pain and radiologic signs of fecal impaction assessed before and after lavage both decreased significantly (P < .0001). During follow-up (mean 15.2 months, range 4 to 26 months), 11 patients required a total of 38 (range one to nine) additional doses of Golytely. Seven patients drank the solution at home (21 treatments); only two patients chose a nasogastric tube. In ten patients with symptoms of recurrent distal intestinal obstruction syndrome prior to institution of therapy, duration of hospitalization was significantly reduced by this treatment (5.1 ± 7.6 v 2.3 ± 6.3 hospital days per annum, P < .02). It is concluded that intestinal lavage is a well-accepted, safe, and effective therapy for distal intestinal obstruction syndrome in patients with cystic fibrosis.
Key Words: distal intestinal obstruction syndrome cystic fibrosis intestinal lavage
Submitted on December 28, 1987
Accepted on June 23, 1988
This article has been cited by other articles:
![]() |
P. R. Durie, G. Kent, M. J. Phillips, and C. A. Ackerley Characteristic Multiorgan Pathology of Cystic Fibrosis in a Long-Living Cystic Fibrosis Transmembrane Regulator Knockout Murine Model Am. J. Pathol., April 1, 2004; 164(4): 1481 - 1493. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Gilljam, C. Chaparro, E. Tullis, C. Chan, S. Keshavjee, and M. Hutcheon GI Complications After Lung Transplantation in Patients With Cystic Fibrosis Chest, January 1, 2003; 123(1): 37 - 41. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. A. Gremse, J. Hixon, and A. Crutchfield Comparison of Polyethylene Glycol 3350 and Lactulose for Treatment of Chronic Constipation in Children Clinical Pediatrics, May 1, 2002; 41(4): 225 - 229. [Abstract] [PDF] |
||||
![]() |
R. Wyllie Gastrointestinal Manifestations of Cystic Fibrosis Clinical Pediatrics, November 1, 1999; 38(12): 735 - 738. [PDF] |
||||